Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$48.72 USD
+1.25 (2.63%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $48.67 -0.05 (-0.10%) 5:28 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Apellis Pharmaceuticals, Inc. (APLS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$80.75 | $110.00 | $57.00 | 69.50% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Apellis Pharmaceuticals, Inc. comes to $80.75. The forecasts range from a low of $57.00 to a high of $110.00. The average price target represents an increase of 69.5% from the last closing price of $47.64.
Analyst Price Targets (16)
Broker Rating
Apellis Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 6.25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 11 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.47 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
4/15/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
4/9/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
3/27/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Hold | Hold |
2/6/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
11/3/2023 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 16 |
Average Target Price | $80.75 |
LT Growth Rate | 38.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.55 |